Simplify's take
What believers are saying
- On November 9, 2026, JANX011 showed initial healthy-volunteer data supporting autoimmune expansion.
- First-patient JANX013 dosing in 2026 expands the TRACIr platform beyond prostate-only dependence.
- JANX007 continues dose optimization and darolutamide cohorts, preserving near-term oncology readouts.
What critics are saying
- JANX011 remains unproven in autoimmune patients until 2027 ITP and RA studies start.
- JANX007 and JANX014 still depend on Phase 1b efficacy signals, not registrational data.
- If JANX011 disappoints, Janux's ARM platform loses its first clinical proof and valuation support.
What makes JANX unique
- JANX011, JANX007, and JANX013 showcase two proprietary platforms across autoimmune and prostate cancer.
- Janux's TRACTr and ARM chemistries aim for tumor activation and B-cell depletion.
- Janux retains $945.7 million cash, funding multiple shots on goal through 2027.
Help us improve and share your feedback! Did you find this helpful?